Even as MedImmune Inc. officials promise hundreds of new hires within the year, new owner AstraZeneca has identified $245 million in redundant annual expenses between the two companies.
At an Aug. 9 regional technology gathering, David Mott, MedImmune's president and CEO and an AstraZeneca senior executive, said the companies are in the final stages of deciding how to combine; a process that will map out the geography of the redundant spending.
At an Aug. 9 regional technology gathering, David Mott, MedImmune's president and CEO and an AstraZeneca senior executive, said the companies are in the final stages of deciding how to combine; a process that will map out the geography of the redundant spending.
London-based AstraZeneca, which bought MedImmune in June, has said it wants the redundancies eliminated by 2010.
Source
Source
No comments:
Post a Comment